VSIG4: a Prominent B7 Family Costimulatory Molecule or Complement Receptor in Cancers and Inflammatory Diseases!
VSIG4: a Prominent B7 Family Costimulatory Molecule or Complement Receptor in Cancers and Inflammatory Diseases!On November 28, 2022, Cancer Letters reported a review paper entitled "The biology of VSIG4: Implications for the treatment of immune-mediated inflammatory diseases and cancer", which describes the prominent roles of VSI...
Detailed information

Epitope Tags Overview
Epitope Tags OverviewIn 1984, S Munro and H R Pelham developed a technique to promote the purification and detection of recombinant proteins, in which an oligonucleotide encoding a peptide was fused to the protein of interest and the target ...
Detailed information

GPCR Drugs Discovery
GPCR Drugs DiscoveryAs the largest membrane protein family in the known human genome, G protein-coupled receptors (GPCRs) have glittered star proteins, which have been favored by pharmaceutical companies in recent years. GPCR is responsible...
Detailed information

Monoclonal Antibody Drugs Overview
Monoclonal Antibody Drugs OverviewIn 1982, Humulin (human insulin), the world's first recombinant drug, was approved for marketing. This is a milestone in the development of drug access from chemical synthesis or extraction of Chinese medicine to biotech...
Detailed information

SLC39A6/ZIP6: a Key Member of Zinc Transporters, a Novel Targeting Antigen of ADC!
SLC39A6/ZIP6: a Key Member of Zinc Transporters, a Novel Targeting Antigen of ADC!Presently, ADC competition heats up in global biotech or pharmaceuticals companies. According to the Pharmsnap database, there are nearly 100 partnered or licensed deals based on ADC new drugs, which has an estimated val...
Detailed information

What You Have To Know about Lung Cancer
What You Have To Know about Lung CancerLung cancer is the leading cause of cancer deaths in both men and women in the U.S. and worldwide. It claims more lives each year than do colon, prostate, ovarian and breast cancers combined, and the cause of lung cancer...
Detailed information

TMEFF2: a Tumor-Specific Methylated Biomarker, a Novel Target in Multiple Cancers
TMEFF2: a Tumor-Specific Methylated Biomarker, a Novel Target in Multiple CancersThe European Society for Medical Oncology (ESMO) Congress 2022 was held in Paris, 9-13 September 2022. As the most influential oncology platform for clinicians and researchers globally, the event brings the new opportuni...
Detailed information

CD93, A Rising Star in Anti-Tumor Therapy
CD93, A Rising Star in Anti-Tumor TherapyIn August this year, Jia et al., from the School of Life and Pharmacy of the Dalian University of Technology, published a paper entitled "CD93 Promotes Acute Myoid Leukemia Development and IS A Potential Therapeutic Targ...
Detailed information

CD20 Monoclonal Antibodies Drugs: There is an Explosion of New mAbs Against CD20!
CD20 Monoclonal Antibodies Drugs: There is an Explosion of New mAbs Against CD20!On August 23, 2022, Sinocelltech Group Ltd. from China's NMPA has received marketing approval for its recombinant chimeric anti-CD20 monoclonal antibody--Ripertamab (SCT-400), to treat patients with CD20-positive diffuse...
Detailed information

Get An Overview of His-Tag
Get An Overview of His-TagIn analyzing the structure and function of recombinant proteins, the most important thing is to get pure recombinant proteins. Therefore, various methods have been explored to isolate high-purity recombinant proteins. Am...
Detailed information

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalizationX